Omada Health filings from July 9, 2026, reveal that top executives sold over $3.2 million in company stock. The CEO, CFO, and CAO completed these transactions between late June and early July.
Executives executed the sales under pre-arranged Rule 10b5-1 trading plans adopted in March 2026. While these plans schedule trades in advance, the collective volume from multiple leaders has drawn investor scrutiny.
The dispositions occurred just over one year after the company’s initial public offering. This selling activity contrasts with a generally positive Buy consensus currently held by Wall Street analysts.